1.02
-0.0132(-1.28%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
December 09, 2021
| Name | Title | Pay | Year Born |
| Mr. Alon Ben-Noon | Co-Founder, Chief Executive Officer & Director | 366,000 | 1979 |
| Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer | 188,000 | 1979 |
| Ms. Hagit Binder | Chief Operation Officer | 218,000 | 1978 |
| Mr. Or Eisenberg | Chief Financial Officer | 279,000 | 1981 |
| Dr. Ferenc Tracik M.D. | Chief Medical Officer | 412,000 | 1964 |
| Ms. Yael Barak | Vice President of Quality & Compliance | 0 | 1970 |
| Mr. Eidan Loushi | C.R.A. | 0 | N/A |
| Ms. Keren Pushett | Head of HR | 0 | N/A |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.